Russell Devore, MD

Articles by Russell Devore, MD

Paclitaxel, Carboplatin, and Radiation Therapy for Non-Small-Cell Lung Cancer

ByHak Choy, MD,Wallace Akerley, MD,Russell Devore, MD

January 2nd 1998

Preclinically, the taxanes appear to potentiate radiation more effectively than do the platinum compounds. In our phase I trial (LUN-17) in patients with advanced non-small-cell lung cancer, we defined the maximum tolerated

Paclitaxel and Vinorelbine in Non-Small-Cell Lung Cancer

ByAlex Y. Chang, MD,Cindy Gu, MD,Robert Asbury, MD,Russell Devore, MD,Peter Keng, MD

October 2nd 1997

Paclitaxel (Taxol) and vinorelbine (Navelbine) are both microtubule toxins but with opposite mechanisms of action. Paclitaxel promotes the assembly of microtubules, whereas vinorelbine prevents microtuble assembly.

Latest Updated Articles

Paclitaxel and Vinorelbine in Non-Small-Cell Lung Cancer
Published: October 2nd 1997 | Updated:
Paclitaxel, Carboplatin, and Radiation Therapy for Non-Small-Cell Lung Cancer
Published: January 2nd 1998 | Updated:

Russell Devore, MD

Articles by Russell Devore, MD

Paclitaxel, Carboplatin, and Radiation Therapy for Non-Small-Cell Lung Cancer

Paclitaxel and Vinorelbine in Non-Small-Cell Lung Cancer

Latest Updated Articles

Trending on CancerNetwork

Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma

Frontline Immunotherapy Improves OS Vs BRAF/MEK Inhibitors in BRAF+ NSCLC

FDA Issues CRL for Dasatinib in CML/ALL

Oral SERD Regimen May Prolong Efficacy in Second-Line Breast Cancer Care

Key Takeaways From IMS Real-World Data on Managing Step-Up Dosing in Relapsed/Refractory Multiple Myeloma